Hindustan Times (Jalandhar)

Hyd centre to grow virus in human cells for in vitro testing

- Jayashree Nandi letters@hindustant­imes.com

NEWDELHI: The Hyderabad-based Centre for Cellular and Molecular Biology (CCMB) will attempt to grow SARS-CoV-2 in human cell lines, enabling in vitro ( literally, in a test tube) testing of potential drugs and vaccines against Covid-19. Experts said this could expedite testing of new drugs that have not been tried on humans before.

According to a statement from the Science and Technology ministry on Tuesday, CCMB will partner with cell therapy company, Eyestem Research Private Limited to develop these cell lines. The research team will use Eyestem’s human lung epithelial cell culture system provided as part of its anti-covid screening (ACS) platform to understand the molecular and pathologic­al characteri­stics of SARS-CoV-2.

“Culturing the virus outside the human host is a technologi­cal challenge that needs to be overcome. Eyestem’s cell culture system expresses the ACE2 receptor (an enzyme the SarsCov-2 virus uses to enter the body) and other genes that are key determinan­ts of viral entry and replicatio­n. We hope that employing this system will allow the CCMB team to grow the virus predictabl­y and thereby open up the potential for the drug screening and vaccine developmen­t strategies”, said Dr Rakesh Mishra, Director, CCMB.

Before human trials new drugs should be tested in vitro and then in animals, said Dr Shobha Broor, former head of the department of virology at the

All India Institute of Medical Sciences. “For the re-purposed drugs being tried for Covid 19, there is some evidence in vitro because they have been tried for other viruses. For different viruses, different cell lines are need for testing efficacy. If we establish this system of testing Covid 19 drugs, whenever we have a new drug it can be tested quickly in the human lung epithelial cell line,” she added.

In another statement, the ministry said Institute of Genomics and Integrativ­e Biology (CSIR-IGIB) and Tata Sons have signed an agreement for licensing know-how for a paper strip based test named Feluda for rapid diagnosis of Covid 19.

Dr Anurag Agrawal, DirectorIG­IB said the technology was conceived and developed at CSIR IGIB and utilizes an indigenous­ly developed cutting edge CRISPR Cas9 technology to specifical­ly recognize the Covid 19 sequence in a sample. A combinatio­n of CRISPR biology and paper-strip chemistry leads to a visible signal readout on a paper strip that can be rapidly assessed for establishi­ng the presence of viral infection in a sample. The test is named after Satyajit Ray’s fictional detective Feluda.

CCMB WILL PARTNER

WITH EYESTEM AND USE ITS HUMAN LUNG EPITHELIAL CELL TO UNDERSTAND THE CHARACTERI­STICS OF SARS-COV-2

 ?? AP ?? Doctors hope this will aid in developmen­t of drugs and vaccines.
AP Doctors hope this will aid in developmen­t of drugs and vaccines.

Newspapers in English

Newspapers from India